Periocular Triamcinolone and Photodynamic Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration

Ophthalmology

Volumn 114, Issue 9, 2007, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CORTICOSTEROID; FLUORESCEIN; TRIAMCINOLONE ACETONIDE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PTOSIS; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 34548274550     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.03.071     Document Type: Article

References (37)

1. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 117 (1999) 1329-1345
3. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 131 (2001) 541-560
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, and Verteporfin in Photodynamic Therapy Study Group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136 (2003) 407-418
5. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123 (2005) 448-457
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report no. 3. Arch Ophthalmol 120 (2002) 1443-1454
7. Schmidt-Erfurth U., Laqua H., Schlotzer-Schrehard U., et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120 (2002) 835-844
8. Ciulla T.A., Criswell M.H., Danis R.P., and Hill T.E. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 119 (2001) 399-404
9. Kato A., Kimura H., Okabe K., et al. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide. Retina 25 (2005) 503-509
10. Dees C., Arnold J.J., Forrester J.V., and Dick A.D. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol 116 (1998) 1456-1461
11. Flaxel C.J., Owens S.L., Mulholland B., et al. The use of corticosteroids for choroidal neovascularisation in young patients. Eye 12 (1998) 266-272
12. Hogan A., Behan U., and Kilmartin D.J. Outcomes after combination photodynamic therapy and immunosuppression for inflammatory subfoveal choroidal neovascularisation. Br J Ophthalmol 89 (2005) 1109-1111
13. Holekamp N.M., Thomas M.A., and Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 139 (2005) 421-428
14. Martidis A., Miller D.G., Ciulla T.A., et al. Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization. J Ocul Pharmacol Ther 15 (1999) 425-428
15. Smithen L.M., and Spaide R.F. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am J Ophthalmol 138 (2004) 884-885
16. Ranson N.T., Danis R.P., Ciulla T.A., and Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. Br J Ophthalmol 86 (2002) 527-529
17. Penfold P.L., Gyory J.F., Hunyor A.B., and Billson F.A. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 23 (1995) 293-298
18. Challa J.K., Gillies M.C., Penfold P.L., et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 26 (1998) 277-281
19. Danis R.P., Ciulla T.A., Pratt L.M., and Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20 (2000) 244-250
20. Spaide R.F., Sorenson J., and Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110 (2003) 1517-1525
21. Spaide R.F., Sorenson J., and Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112 (2005) 301-304
22. Helm C.J., and Holland G.N. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 120 (1995) 55-64
23. Freeman W.R., Green R.L., and Smith R.E. Echographic localization of corticosteroids after periocular injection. Am J Ophthalmol 103 (1987) 281-288
24. Hyndiuk R.A., and Reagan M.G. Radioactive depot-corticosteroid penetration into monkey ocular tissue. 1. Retrobulbar and systemic administration. Arch Ophthalmol 80 (1968) 499-503
25. Thach A.B., Dugel P.U., Flindall R.J., et al. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology 104 (1997) 2003-2008
26. Dupont W.D., and Plummer Jr. W.D. Power and sample size calculations: a review and computer program. Control Clin Trials 11 (1990) 116-128
27. Macular Photocoagulation Study: MPS Manual of Procedures (1991), National Technical Information Service, Springfield, VA NTIS Publication PB91-207903
28. Collaborative Ocular Melanoma Study. COMS Manual of Procedures (1995), National Technical Information Service, Springfield, VA NTIS Publication PB95-179693
29. Submacular Surgery Trials Group. SST Manual of Procedures (1998), National Technical Information Service, Springfield, VA NTIS Publication PB98-166648
30. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol 137 (2004) 683-696
31. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group, Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no. 2. Arch Ophthalmol 121 (2003) 1253-1268
32. Submacular Surgery Trials Research Group. Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trial+s (SST): SST report no. 8. Retina 25 (2005) 253-268
33. Van de Moere A., Sandhu S.S., Kak R., et al. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 112 (2005) 1896-1903
34. Jonas J.B., Spandau U.H., Harder B., et al. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 139 (2005) 1073-1079
35. Gillies M.C., Simpson J.M., Luo W., et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 121 (2003) 667-673
36. Bonini-Filho M.A., Jorge R., Barbosa J.C., et al. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 46 (2005) 3845-3849
37. Cardillo J.A., Melo Jr. L.A., Costa R.A., et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology 112 (2005) 1557-1563